Eriko Tokunaga

机构：National Hospital Organization Kyushu Cancer Center, Fukuoka Hospital, National Hospital Organization · ORCID：0000-0002-1640-5315

发表论文 380 篇 · 总被引 14308 次 · h-index 50

代表论文

• HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer (2025 · Journal of Clinical Oncology · 被引 10)
• Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo). (2026 · Journal of Clinical Oncology · 被引 3)
• Abstract GS2-09: The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) (2026 · Clinical Cancer Research · 被引 3)
• Abstract PD5-08: Circulating Tumour DNA (ctDNA) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial (2026 · Clinical Cancer Research · 被引 2)
• Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer (2026 · Clinical Cancer Research · 被引 2)
• ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i). (2026 · Journal of Clinical Oncology · 被引 1)